Sign inJoin waitlistJoin the waitlist

Burton Appel

Associate Director, Pediatric Hematology/Oncology · Hackensack Meridian Health

Credentials: · · · ·

History

Data Safety Monitoring Board Department · Hackensack Meridian Health
Present
Hackensack Meridian Health
Present

Pediatric Hematology Oncology
University of Chicago Medical Center
1993–1996
Pediatrics
University of Chicago Medical Center
1990–1993
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1986–1990

Research

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
British Journal of Haematology · 2017 · 116 citations
Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience
Pediatric Blood & Cancer · 2021 · 90 citations
Effects of insulin and dexamethasone on lipoprotein lipase in human adipose tissue
American Journal of Physiology-Renal Physiology · 1992 · First of 2 authors · 82 citations

Cindy Schwartz
7 papers
Kara Kelly
6 papers
NK
Nina Kadan-Lottick
6 papers
Louis Constine
4 papers
Debra Friedman
3 papers
Jason Mendoza
3 papers
Kenneth Tercyak
3 papers
Lianna Marks
3 papers · 1 as a fellow
PE
Peter Erhlich
3 papers
RH
Robert Hutchison
3 papers
Andrew Smitherman
2 papers
FK
Frank Keller
2 papers

Clinical trials

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
Principal investigator · Completed · Phase 2
Children's Oncology Group
2006–2026
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Site PI · Recruiting
St. Jude Children's Research Hospital
2024–2028
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031